Clinical Trial Update: A Trial of Tarlatamab in Patients With Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC) and ECOG PS 2 [Phase 2]

View source ↗

Summary

Phase 2 study evaluating Tarlatamab in pretreated extensive-stage small cell lung cancer with ECOG performance status 2 is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extensive-stage Small Cell Lung Cancer
• Small Cell Lung Cancer

Drugs mentioned

• Tarlatamab

Snippet

Sponsor: ETOP IBCSG Partners Foundation | Conditions: Extensive Stage Lung Small Cell Cancer | Phase 2 | Status: RECRUITING